Researchers at the University of Illinois recently re-engineered small molecules to disrupt toxic RNA repeats involved in DM2.
Exciting news out of Washington, DC: the House of Representatives' Energy & Commerce Committee ordered the MD-CARE Act to advance to the House floor!
The DMCRN was established a little over a year ago to evaluate potential DM treatments, prepare possible clinical trial sites and conduct important DM research studies.
Peter S. Harper, M.D., University Research Professor (Emeritus), Cardiff University
© Myotonic Dystrophy Foundation. All rights reserved.
Sitemap | User Agreement